Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
about
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivityUpdate on the therapeutic potential of PDE4 inhibitors.Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease.Modulation of the cAMP signaling pathway after traumatic brain injury.Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesteraseDistinct monocyte gene-expression profiles in autoimmune diabetesPersistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.Small molecule inhibitors in the treatment of cerebral ischemia.Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?Novel 5,6-dihydropyrazolo[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease.The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice.Protection by pentoxifylline of diazinon-induced toxic stress in rat liver and muscle.Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes.Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.Identifying the antiasthmatic target of doxofylline using immobilized β2 -adrenoceptor based high-performance affinity chromatography and site-directed molecular docking.Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
P2860
Q27642760-98C8C17B-A861-4555-9C1B-1B98092CA0BFQ34107488-8896CB8E-76A8-42BC-A024-0F058D598BFEQ34997202-91F59E6C-C7D6-4324-93B3-0FFD87A6C056Q36276090-017B1B0B-0148-474B-962E-D64B703872F4Q36855547-DB12F578-8B59-488E-8CA1-4A83715382FBQ36906389-CFFFBE46-C1F5-4E39-8C87-2C3D6E74F9DEQ37625928-9545B074-3BE8-4391-90C2-9B1F6A2E9EA4Q38184644-D839658B-1F9D-455D-AC57-A75549D94E23Q38243490-2A6E3BEE-B875-409D-BAA5-43CF11754B2FQ38978977-3B78FB96-740C-461B-9E00-74605BC380FEQ41528091-F2A465AC-558D-4A5A-A626-82DC95835B0DQ42975073-87F9B30E-3C23-428D-BA41-062EA9C76F16Q43171690-B2A846A3-88C8-48BB-A3DD-D39B7F6C68ECQ43215782-CDC754B8-2516-411D-BFFE-18784C33A722Q44852650-55479843-C535-4242-B137-71910D153321Q46142907-0DDDFC6D-CF6E-4F34-AEAB-C1813A1BD421Q48093627-CEE3C8F7-4856-40C6-8616-62BE9DE2C10BQ51334162-481B346C-05B0-435D-A58A-B0DFE534E6D0Q52610098-0E9E58CB-139F-41D5-A40A-33C9E883FE64
P2860
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@ast
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@en
type
label
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@ast
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@en
prefLabel
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@ast
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@en
P1476
Phosphodiesterase 4 inhibitors ...... asthma and other pathologies.
@en
P2093
Dal Piaz V
Giovannoni MP
P304
P356
10.1016/S0223-5234(00)00179-3
P577
2000-05-01T00:00:00Z